About the project
The European Academy for Biomedical Science (ENABLE) conference series, rebranded in 2022 FEBS-IUBMB-ENABLE conference series, is based on a successful project funded by the EU H2020 Research and Innovation Programme. Since 2017, the ENABLE consortium has promoted international, interdisciplinary 3-day conferences organised by and for young researchers from the molecular life sciences disciplines, bringing together up to 300 participants from all over the world. Each one of these annual gatherings has been hosted by a partner research institute involved in the consortium. Since the launch of ENABLE, FEBS and IUBMB have been the main sponsors of the events, and have now joined forces to give continuity to these successful events and to offer additional research institutes devoted to molecular life sciences worldwide the opportunity to host and actively participate in the organisation of one of these conferences.
The new adhered institutions, selected by a competitive call, become the hosts of the FEBS-IUBMB-ENABLE conference, and get involved in the project for a 2-year period. The roadmap below summarizes the wonderful journey the ENABLE conference has been since 2017 and is still going on as the FEBS-IUBMB-ENABLE conference, bringing together young researchers from around the world. In 2024 we also went further and took the conference outside Europe.
IRB Barcelona is a world-class research center devoted to understanding fundamental questions about human health and disease. It was founded in October 2005 by the Government of Catalonia and the University of Barcelona. The Institute’s missions include conducting multidisciplinary research of excellence at the unique interface between biology, chemistry and medicine, providing high-level training in the biomedical sciences to staff, students and visitors, driving innovation through active technology transfer to the benefit of society, and actively participating in an open dialogue with the public through a series of engagement and education activities.
The mission of the Radboud Institute for Molecular Life Sciences (RIMLS) is to achieve a greater understanding of the molecular mechanisms of disease.
By integrating fundamental and clinical research, the institute obtains multifaceted knowledge of (patho)physiological processes. To have a significant impact on healthcare, these findings are translated into diagnostics, therapeutics and personalized treatment strategies.
The multi-disciplinary approach to research in molecular life science is reflected in an established RIMLS Graduate School with a dedicated 2-year research honours MSc degree in Molecular Mechanisms of Disease and a follow-up 4-year PhD program.
Novo Nordisk Foundation Center for Protein Research (CPR) was established at the Faculty of Health and Medical Sciences, University of Copenhagen to promote basic and applied discovery research on human proteins of medical relevance. CPR aims to assemble protein-related technologies with revolutionary potential for understanding the complex wiring of biological systems and disease processes.
The vision of the Center is to be the world’s leading center in integrative protein technologies and their application to accelerate understanding of the biological processes underlying health and disease.
This is achieved by developing integrated protein technology platforms and management systems for large heterogeneous data to advance the understanding of complex protein networks in fundamental biology and disease, educating the next generation of top-tier protein scientists and becoming an unmatched global partner in protein research.
SEMM is a private foundation established in 2001 by a joint ministerial decree of three Italian Ministries, Health, Treasure, and Education, Scientific and Technological Research. The mission of the Scuola Europea di Medicina Molecolare (SEMM) is to promote the training and research of young scientists within emerging sectors of biomedicine.
SEMM operates within research centers of excellence bridging together higher education and front-line research training. Science covers virtually every aspect of modern Cell Biology and Molecular Biology, both from the basic and applied research points of view.
SEMM manages in agreement with the University of Milan and Naples, a PhD program in Systems Medicine which includes 5 curricula: Molecular Oncology, Human Genetics, Computational Biology, Medical Nanotechnology and Foundations of the Life Sciences Bioethics and Cognitive Sciences and a post doc program SIPOD.
Founded in 1964, The Federation of European Biochemical Societies (FEBS) has become one of Europe’s largest organizations in the molecular life sciences, with over 35,000 members across more than 35 biochemistry and molecular biology societies (its ‘Constituent Societies’) in different countries of Europe and neighbouring regions.
As a charity, FEBS promotes and supports biochemistry, molecular biology, cell biology, molecular biophysics and related research areas through its journals, Congress, Advanced Courses, Fellowships and other initiatives.
There is an emphasis in many programmes on scientific exchange and cooperation between scientists working in different countries, and on promotion of the training of early-career scientists. Information about FEBS is available at www.febs.org.
The International Union of Biochemistry and Molecular Biology – founded in 1955 – unites biochemists and molecular biologists in 79 countries and regions that belong to the Union as an Adhering Body or Associate Adhering Body represented by a biochemical society, a national research council or an academy of sciences.
The Union is devoted to promoting research and education in biochemistry and molecular biology throughout the world and gives particular attention to providing opportunities to students, postdoctoral fellows, and junior investigators to advance their training.
The Lee Kong Chian School of Medicine, a partnership between Nanyang Technological University, Singapore (NTU Singapore) and Imperial College London (Imperial) is training doctors who put patients at the centre of their exemplary care. The School, which offers both undergraduate and graduate programmes, is named after local philanthropist Tan Sri Dato Lee Kong Chian. Officially opened on 28 August 2017 by the then Deputy Prime Minister of Singapore Mr Teo Chee Hean, LKCMedicine aims to be a model for innovative medical education and a centre for transformative research. The School’s primary clinical partner is the National Healthcare Group, a leader in public healthcare recognised for the quality of its medical expertise, facilities and teaching.
Graduates of the five-year undergraduate medical degree programme that started in 2013 will have a strong understanding of the scientific basis of medicine, with an emphasis on technology, data science and the humanities. The School’s first doctors graduated in 2018 with Bachelor of Medicine and Bachelor of Surgery (MBBS) degrees awarded jointly by NTU Singapore and Imperial.
The University of Cologne (UoC) covers a broad field of disciplines with a strong focus in Life Sciences and has a long history of intense scientific and strategic collaboration that connects basic research to translational medicine. The Faculty of Mathematics and Natural Sciences (FMNS), as well as the Faculty of Medicine (FM) along with the University Hospital Cologne (UHC) have developed a vibrant interdisciplinary Life Science Campus consisting of the Center for Molecular Medicine Cologne (CMMC), the Cologne Excellence Cluster Cellular Stress Responses in Aging-Associated Diseases (CECAD), the Cologne Center for Genomics (CCG), as well as the Max Planck Institutes for Biology of Ageing (MPI-AGE) and Metabolism Research (MPI-MR) along with seven collaborative research centres.
The Institute of Biomedicine of Seville (IBiS), was created in 2006 as a multidisciplinary biomedical research centre within the complex that houses the Virgen del Rocío University Hospital, a centre of high-level care, education and research.
Its principal objective is to undertake competitive research at an international level on the causes of the most prevalent pathologies in the population, and to develop new methods for their diagnosis and treatment.
IBiS is based on fundamental research at the molecular and cellular level with a view to promote the rapid transfer of knowledge to the clinical setting, at the same time improving the quality of clinical and epidemiological research.